Practical device for automated monitoring of neovascularization in diabetic retinopathy - Project Summary Diabetic retinopathy (DR) is a leading cause of blindness among working-age adults, with over 9.6 mil- lion Americans affected. The most sight-threatening phase of DR is proliferative diabetic retinopathy (PDR), marked by the growth of abnormal retinal blood vessels (neovascularization, NV). Timely detec- tion of NV is critical for preventing irreversible vision loss. The gold standard for detecting and moni- toring NV in DR patients has long been fluorescein angiography (FA), but it is invasive and resource- intensive. Fundus photography is widely available and non-invasive, but it does not provide enough contrast to visualize tiny microvessels and hence to promptly detect early NV. OCT angiography (OCTA) is an interesting noninvasive alternative imaging technique, but it has a limited field of view, it requires expert readers and it is too costly and complex for widespread adoption, particularly in rural resource- limited settings and non-traditional settings such as retail locations (e.g., CVS, Walgreens, Costco). This project proposes to develop and validate an innovative imaging device, retinal full-field amplitude speckle decorrelation angiography (R-FASDA), based on our proprietary adaption of laser speckle im- aging. R-FASDA delivers high-resolution, noninvasive visualization of retinal vasculature at a cost and complexity dramatically lower than OCTA, with a wider field of view comparable to fundus photography. This device could enable NV detection not only in tertiary ophthalmology centers, but also in rural underserved resource-limited areas clinics, retail locations (e.g., CVS, Walgreens, Costco), mobile clinics, and primary care clinics, thereby improving early detection rates and enabling broader screening programs. In Aim 1, we will expand the prototype’s field of view from 7.5 to 45 degrees, and in Aim 2, we will con- duct a pilot study in DR patients to establish equivalence between R-FASDA and OCTA. Following successful completion, we will be well positioned to produce five clinical prototypes, launch pivotal multi-center trials, and develop AI tools for automated NV detection. This technology not only promises a paradigm shift in DR screening (especially in underserved and non-traditional settings), but also holds potential for other retinal vascular diseases such as wet age-related macular degeneration.